Department of Personalized Medicine, Tbilisi State Medical University, Tbilisi, Georgia
Research Article
Targeting Glycolysis in Tumor Cells: Therapeutic Inhibition of GLUT1 and LDH-A Using Phloretin and Melatonin for Metabolic Reprogramming and Tumor Regression in Triple Negative Breast Cancer
Author(s): Alexandre Tavartkiladze*, Gaiane Simonia, Ruite Lou, Pati Revazishvili, Dinara Kasradze, Maia Maisuradze, Rusudan Khutsishvili, Irine Andronikashvili and Pirdara Nozadze
Background: Glycolysis in tumor cells is a critical pathway for energy production and biomass accumulation, allowing rapid cell proliferation even in hypoxic conditions. This metabolic adaptation, known as the Warburg effect is characterized by glucose uptake via Glucose Transporter 1 (GLUT1) and the conversion of pyruvate to lactate by Lactate Dehydrogenase-A (LDH-A). Inhibition of glycolysis disrupts these pathways and may result in tumor regression. Phloretin, a natural GLUT1 inhibitor and melatonin, an agent known to downregulate LDH-A, show potential in glycolysis-targeted cancer therapy.
Materials and methods: A comparative study was conducted to evaluate the biochemical dynamics of glycolysis inhibition in patients with advanced Triple Negative Breast Cancer (TNBC) using phloretin and melatonin. Fifty-two women were .. View More»
DOI:
10.35248/IGOA.24.9.235